Hotgen(SH:688068) Xin Lang Zheng Quan·2025-10-31 01:56Core Insights - The stock price of Hotgen Biotech increased by 2.09% on October 31, reaching 150.27 CNY per share, with a total market capitalization of 13.93 billion CNY [1] - Year-to-date, the stock has risen by 143%, but it has seen a decline of 6.35% in the last five trading days, 13.46% in the last 20 days, and 22.94% in the last 60 days [1] - The company has reported a significant decrease in revenue and net profit for the first nine months of 2025, with revenue of 310 million CNY, down 19.80% year-on-year, and a net loss of 109 million CNY, a decrease of 168.12% [2] Financial Performance - Hotgen Biotech's main business revenue composition includes 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1] - Cumulative cash dividends since the company's A-share listing amount to 440 million CNY, with 17.34 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 12.90% to 7,833, while the average circulating shares per person decreased by 11.43% to 11,835 shares [2] - The top ten circulating shareholders include various funds, with notable changes in holdings among them, such as a decrease in shares held by Huatai-PineBridge Innovation Medicine Mixed A and an increase by ICBC Frontier Medical Stock A [3]